How Medtronic Makes its Money: Revenue Breakdown
A breakdown of Medtronic (MDT) financials. See how Medtronic makes money from Cardiovascular, Neuroscience, Medical Surgical, and more using their 2024 annual report.
How Does Medtronic Make its Money?
Medtronic is the world’s largest pure-play medical device company, operating across four segments: Cardiovascular, Medical Surgical, Neuroscience, and Diabetes. Founded in 1949 as a pioneer in cardiac pacemakers, the company now offers products ranging from heart valves and spinal implants to insulin pumps and surgical robots. Medtronic serves hospitals, physicians, clinicians, and patients in more than 150 countries. The company has been in a multi-year transformation effort to accelerate innovation and improve operational execution after a period of underperformance.
Medtronic (MDT) Business Model
Medtronic Competitors
Medtronic’s key competitors and comparable public companies in the medical devices sector include Stryker, Intuitive Surgical, Boston Scientific, and Abbott Laboratories. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Medtronic stacks up by comparing their revenue breakdown, margins, and growth metrics.
Revenue Breakdown
| Segment | 2024 | 2023 | YoY Growth |
|---|---|---|---|
| Cardiovascular | $12,300 | $11,600 | +6.0% |
| Neuroscience | $9,800 | $9,400 | +4.3% |
| Medical Surgical | $8,600 | $8,200 | +4.9% |
| Diabetes | $2,700 | $2,500 | +8.0% |
| Total Revenue | $33,400 | $31,200 | +7.1% |
Cardiovascular — 37% of Revenue
Products and therapies for cardiac rhythm management (pacemakers, implantable defibrillators), structural heart (transcatheter aortic valve replacement — TAVR), coronary and peripheral vascular interventions, and cardiac surgery. Revenue grew 6.0% to $12.3 billion in 2024. This is Medtronic’s largest and historically most important segment — the company invented the battery-powered pacemaker that launched the modern medical device industry.
The Cardiovascular portfolio includes several market-leading franchises. Cardiac Rhythm Management (pacemakers and ICDs) is a mature, duopoly market where Medtronic and Abbott control 70%+ of global share, with recurring revenue from pulse generators that need replacement every 7-10 years and leads that require ongoing monitoring. The structural heart business — centered on the Evolut TAVR system for minimally invasive aortic valve replacement — is higher growth, competing with Edwards Lifesciences’ Sapien platform for the expanding population of patients eligible for transcatheter valve procedures. Medtronic’s aortic, coronary, and peripheral vascular portfolios include stents, balloons, and drug-coated devices used in catheterization labs worldwide.
Neuroscience — 29% of Revenue
Products for cranial and spinal surgery, neuromodulation (spinal cord stimulation for chronic pain, deep brain stimulation for Parkinson’s disease and essential tremor), and specialty therapies (ear, nose, throat, and pelvic health). Revenue grew 4.3% to $9.8 billion in 2024. The Spine business makes Medtronic one of the two largest spinal implant companies globally (alongside Johnson & Johnson’s DePuy Synthes), providing rods, screws, cages, and biologics used in spinal fusion surgery. Spinal cord stimulation (SCS) for chronic pain management is a high-margin neuromodulation franchise, though it has faced competitive and clinical challenges.
Deep brain stimulation (DBS) for Parkinson’s disease is a unique Medtronic franchise with limited direct competition. The Percept DBS system, which can record and analyze brain activity data, represents the frontier of brain-computer interface technology in medical devices. ENT (ear, nose, throat) products — including powered surgical instruments and navigation systems for sinus surgery — provide a steady, procedure-driven revenue stream.
Medical Surgical — 26% of Revenue
Products for surgical innovation (robotic-assisted surgery, advanced energy, surgical stapling, hernia repair), respiratory and patient monitoring solutions, and renal care (hemodialysis). Revenue grew 4.9% to $8.6 billion in 2024. The most important story in this segment is the Hugo robotic-assisted surgery (RAS) system — Medtronic’s answer to Intuitive Surgical’s da Vinci platform that dominates soft-tissue robotic surgery with 80%+ market share.
Hugo is Medtronic’s highest-stakes product launch in a decade. The system has received CE Mark in Europe and is pursuing FDA clearance for multiple surgical specialties. If Medtronic can successfully capture even 15-20% of the surgical robotics market, it represents a multi-billion dollar revenue opportunity because robotic surgery platforms generate recurring revenue from instruments, accessories, and service contracts for many years after the initial system placement. The respiratory and monitoring portfolio includes ventilators, pulse oximeters, and patient monitoring systems sold to hospitals and respiratory care facilities. Renal care provides hemodialysis products for patients with end-stage kidney disease.
Diabetes — 8% of Revenue
Insulin pumps, continuous glucose monitors (CGMs), and integrated diabetes management systems. Revenue grew 8.0% to $2.7 billion in 2024, the fastest growth rate among Medtronic’s segments. The MiniMed insulin pump franchise has been Medtronic’s diabetes business for decades, and the 780G system with Guardian 4 sensor represents the latest automated insulin delivery technology. The segment has faced intense competition from standalone CGM leaders Dexterity (Dexcom) and Abbott (Libre), as well as newer insulin pump competitors like Insulet (Omnipod) and Tandem Diabetes.
The 8.0% growth marks a significant improvement after several years of market share losses, driven by the 780G system launch and improved sensor accuracy. The Simplera CGM sensor, with a thinner and simpler design, is Medtronic’s attempt to close the technology and user experience gap with Dexcom G7 and Abbott Libre 3.
Medtronic (MDT) Income Statement
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenue | $33,400 | $31,200 |
| Cost of Revenue | $11,300 | $10,700 |
| Gross Profit | $22,100 | $20,500 |
| Operating Expenses | $14,600 | $13,800 |
| Operating Income | $7,500 | $6,700 |
| Net Income | $4,700 | $3,700 |
All values in millions USD unless otherwise stated.
Financial data sourced from Medtronic SEC Filings.
Medtronic (MDT) Key Financial Metrics
- Gross Margin: 66.2%
- Operating Margin: 22.5%
- Revenue Growth: 7.1%
Is Medtronic Profitable?
Yes, Medtronic is solidly profitable with premium margins reflecting the value of its medical device portfolio. The 66.2% gross margin is strong for medical devices and benefits from the high-value, implantable nature of Medtronic’s products — a cardiac pacemaker or TAVR valve commands thousands of dollars per unit with relatively low marginal production costs. The 22.5% operating margin is improving after years of R&D investment in Hugo robotics, next-generation diabetes systems, and new product launches across all four segments. Net income grew 27.0% to $4.7 billion on 7.1% revenue growth, demonstrating significant operating leverage as new products ramp and operational efficiency initiatives take hold. Medtronic generates robust free cash flow deployed through dividends (Medtronic is a Dividend Aristocrat with 47+ consecutive years of dividend increases), share buybacks, and strategic acquisitions to expand its portfolio.
Medtronic (MDT): What to Watch
- Hugo robotic-assisted surgery platform progress — FDA clearance timing, initial system placements, procedure adoption curves, and competitive positioning against Intuitive Surgical’s da Vinci 5 will determine whether Medtronic can capture meaningful share of the surgical robotics market.
- Diabetes segment market share trajectory — The 780G insulin pump and Simplera CGM must demonstrate sustained competitive performance against Dexcom, Abbott, and Insulet. Diabetes revenue growth indicates whether Medtronic’s turnaround in this segment is real and durable.
- TAVR market share and next-gen Evolut platform — The structural heart business is a growth driver, but Medtronic faces Edwards Lifesciences’ entrenched position. New-generation TAVR devices and expansion into lower-risk patient populations drive the growth opportunity.
- Operating margin expansion — After years of elevated R&D spending on Hugo, Simplera, and other pipeline products, Medtronic is targeting margin expansion as these products launch and scale. The trajectory from 22.5% toward 25%+ operating margins is a key financial metric.
- Neuromodulation competitive dynamics — Spinal cord stimulation has faced clinical and competitive headwinds. New therapy innovations (high-frequency stimulation, closed-loop systems) and differentiated outcomes data are needed to stabilize and grow this historically high-margin franchise.
Medtronic (MDT) Financial Summary
Medtronic is the world’s largest pure-play medical device company with a $33.4 billion revenue base spanning Cardiovascular (37%, pacemakers, TAVR), Neuroscience (29%, spine, DBS, ENT), Medical Surgical (26%, Hugo robotics, respiratory, renal), and Diabetes (8%, insulin pumps, CGM). Revenue grew 7.1% in 2024 with acceleration across all segments, and net income surged 27.0% to $4.7 billion as operating leverage kicked in. The 66.2% gross margin and 22.5% operating margin reflect premium medical device economics. The key strategic bets are the Hugo robotic surgery platform challenging Intuitive Surgical’s dominance, the Simplera CGM revitalizing the Diabetes franchise, and continued expansion of TAVR and neuromodulation into larger addressable markets.
Weekly Company Breakdowns — Visualized
See how top companies actually make money. Visual revenue breakdowns delivered free every week.